{"id":"b-peg-interferon-alpha-2a-ribavirin","safety":{"commonSideEffects":[{"rate":"50-80","effect":"Flu-like symptoms (fever, fatigue, myalgia)"},{"rate":"10-30","effect":"Anemia"},{"rate":"5-15","effect":"Neutropenia"},{"rate":"10-20","effect":"Depression/mood changes"},{"rate":"20-40","effect":"Headache"},{"rate":"20-30","effect":"Nausea"},{"rate":"5-10","effect":"Thrombocytopenia"}]},"_chembl":{"chemblId":"CHEMBL2108508","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Peg-interferon alpha-2a is a pegylated form of interferon alpha-2a that binds to interferon-alpha receptors on immune cells, triggering antiviral and immunomodulatory effects including activation of natural killer cells and upregulation of MHC molecules. Ribavirin is a nucleoside analog that inhibits viral RNA-dependent RNA polymerase and depletes guanosine pools, directly suppressing hepatitis C virus replication. The combination provides synergistic antiviral activity.","oneSentence":"Peg-interferon alpha-2a activates innate immune responses against viral infection, while ribavirin inhibits viral RNA synthesis, together targeting hepatitis C virus replication.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:42:50.405Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis C virus infection"}]},"trialDetails":[{"nctId":"NCT02259855","phase":"PHASE1","title":"Pharmacokinetics (PK) of Tipranavir/Ritonavir, Ribavirin, Pegylated Interferon (Peg INF) in Hepatitis C (HCV) Subjects With Mild Hepatic Impairment and in HCV, Hepatitis B (HBV), Hepatitis D Infected Subjects or Alcoholic Cirrhosis With Moderate Hepatic Impairment","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2006-01-01","conditions":"Hepatic Insufficiency","enrollment":36},{"nctId":"NCT00078403","phase":"PHASE2","title":"Pegylated Interferon Alfa-2a Maintenance Therapy and Liver Disease Progression in People Infected With Both HIV and Hepatitis C Virus (HCV)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2004-07","conditions":"HIV Infections, Hepatitis C, Liver Disease","enrollment":333},{"nctId":"NCT00684268","phase":"PHASE2","title":"Intravenous Silibinin in Combination With Peg-interferon and Ribavirin in Nonresponders","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2007-10","conditions":"Hepatitis C","enrollment":70},{"nctId":"NCT01937728","phase":"PHASE4","title":"Tailored Regimens of PEGASYS® and Ribavirin for Genotype 1 Chronic Hepatitis C Patients Trial (TARGET-1)","status":"COMPLETED","sponsor":"Kaohsiung Medical University Chung-Ho Memorial Hospital","startDate":"2010-03","conditions":"Hepatitis C","enrollment":542},{"nctId":"NCT01425970","phase":"PHASE2","title":"Chronically-infected HCV Genotype 2 and 3 Treatment-naive Subjects: Part A: Safety and Efficacy of INX-08189 With Peg IFN Alfa-2a and Ribavirin. Part B: INX-08189 in Interferon Free Treatment With Daclatasvir and/or Ribavirin","status":"TERMINATED","sponsor":"Bristol-Myers Squibb","startDate":"2012-05","conditions":"Hepatitis C","enrollment":210},{"nctId":"NCT01405027","phase":"PHASE4","title":"Impact of Physician Directed Education on Patient Compliance With Hepatitis C Therapy","status":"COMPLETED","sponsor":"Chronic Liver Disease Foundation","startDate":"2011-12","conditions":"Chronic Hepatitis C, Genotype 1","enrollment":197},{"nctId":"NCT01384383","phase":"PHASE2","title":"GS-5885, GS-9451 With Peginterferon Alfa 2a (PEG) and Ribavirin in Treatment-Naïve Subjects With Chronic Genotype 1 Hep C Virus Infection and IL28B CC Genotype","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2011-08","conditions":"Chronic Hepatitis C","enrollment":248},{"nctId":"NCT00703118","phase":"PHASE3","title":"A Safety and Effectiveness Study of Telaprevir in Chronic, Genotype 1, Hepatitis C Patients That Failed Previous Standard Treatment","status":"COMPLETED","sponsor":"Tibotec BVBA","startDate":"2008-10","conditions":"Hepatitis C, Chronic","enrollment":663},{"nctId":"NCT00502099","phase":"PHASE4","title":"Comparison of Pegasys Versus Peg-Intron for Treatment of Chronic Hepatitis C Genotype 4","status":"COMPLETED","sponsor":"Amr Hafez","startDate":"2006-01","conditions":"Hepatitis C","enrollment":217},{"nctId":"NCT00629967","phase":"PHASE4","title":"A Randomized Trial of 24-Week Versus 48-Week Courses of Peginterferon Plus Ribavirin for HCV Genotype-1 Patients","status":"COMPLETED","sponsor":"Kaohsiung Medical University Chung-Ho Memorial Hospital","startDate":"2005-04","conditions":"Chronic Hepatitis C, Genotype","enrollment":200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Pegasys & Robatrol"],"phase":"marketed","status":"active","brandName":"B: Peg-interferon alpha-2a & Ribavirin","genericName":"B: Peg-interferon alpha-2a & Ribavirin","companyName":"Kaohsiung Medical University Chung-Ho Memorial Hospital","companyId":"kaohsiung-medical-university-chung-ho-memorial-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Peg-interferon alpha-2a activates innate immune responses against viral infection, while ribavirin inhibits viral RNA synthesis, together targeting hepatitis C virus replication. Used for Chronic hepatitis C virus infection.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}